Біосиміляри в терапії цукрового діабету 1 типу: потенційні ризики застосування в пацієнтів дитячого віку

О. А. Будрейко

Анотація


Проблема використання біосимілярів інсуліну у хворих на цукровий діабет останніми роками набуває все більшої актуальності через закінчення терміну патентування найефективніших інсулінових препаратів, зокрема золотого стандарту базальної інсулінотерапії гларгіну. В огляді представлено аналіз особливостей перебігу цукрового діабету 1 типу у хворих дитячого віку в аспекті підвищеної імунної реактивності та активного продіабетогенного антитілоутворення. На підставі аналізу численних наукових досліджень обґрунтовано необхідність урахування високого потенційного ризику застосування у дітей та підлітків препаратів інсуліну з непередбаченими властивостями, що характеризує більшість відомих наразі біосимілярів інсуліну «Гларгіну».


Ключові слова


цукровий діабет 1 типу; аналоги інсуліну; біосиміляри; імуногенність; антитілоутворення; діти та підлітки

Повний текст:

PDF

Посилання


Корпачев В.В., Лукашова Р.Г., Мельниченко С.В. та ін. Вміст антитіл до інсуліну у сироватці крові хворих на цукровий діабет, пролікованих різними дозами препаратів інсулінів // Ендокри­нологія. — 2009. — Т. 14, № 1. — С. 108—113.

Корпачев В.В., Мельниченко С.В., Лукашова Р.Г. та ін. Анти­генність інсуліну і методи визначення антитіл до нього у сироватках крові здорових людей та хворих на цукровий діабет // Ендокринологія. — 2005. — Т. 10, № 2. — С. 206—223.

Полетаев А.Б., Будыкина Т.С., Морозов С.Г. Аутоантитела к инсулину, сахарный диабет 1 типа и диабетическая нефропатия // Сахарный диабет. — 2000. — № 4. — С. 12—18.

Armitage M., McCaughey E., Brooks A. et al. Insulin resistance and insulin antibodies: fact or hallowed fiction? // Pract. Diabetes. — 1988. — Vol. 5. — P. 200—202.

Asai M., Kodera T., Ishizeki K. et al. Insulin lispro reduces insulin antibodies in a patient with type 2 diabetes with immunological insulin resistance // Diabetes Res. — Clin. Pract. — 2003. — Vol. 61. — P. 89—92.

Azevedo V.F. Are we prepared to prescribe biosimilars? // Bras. J. Rheumatol. — 2010. — N 50 (3). — Р. 221—224.

Basu A., Service F.J., Yu L. et al. Insulin autoimmunity and hypo­gly­cemia in seven white patients // Endocr. Pract. — 2005. — Vol. 11. — P. 97—103.

Bilbao R., Rica I., Vázquez J.A. et al. Influence of sex and age at onset on autoantibodies against insulin, GAD65 and IA2 in recent onset type 1 diabetic patients // Horm. Res. — 2000.— Vol. 54, N 4. — Р. 181—185.

Bistritzer T., Sack J., Theodor R. et al. Correlation between HbA1c, purified insulin, diabetic control, and insulin antibodies in diabetic children // Horm. Res. — 1984. — Vol. 20. — P. 178—185.

Bolli G., deFeo P., Compagnucci P. et al. Abnormal glucose count­erregulation in insulin-dependent diabetes mellitus: interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion // Diabetes. — 1983. — Vol. 32. — P. 134—141.

Buehler G.J., Conner D. The FDA Process for Approving Generic Drugs. FDA Office of Generic Drugs. http://www.connectlive. com/events/ genericdrugs/2006.

Chase H.P., Arslanian S., White N.H., Tamborlane W.V. Insulin Glargine Versus Intermediate-Acting Insulin as the Basal Component of Multiple Daily Injection Regimens for Adolescents with Type 1 Diabetes Mellitus // J. Pediatr. — 2008. — Vol. 153. — P. 547—553. doi: 10.1016/j.jpeds.2008.04.063.

Chen J.W., Frystyk J., Lauritzen T., Christiansen J.S. Impact of insulin antibodies on insulin aspart pharmacokinetics and pharmacodynamics after 12-week treatment with multiple daily injections of biphasic insulin aspart 30 in patients with type 1 diabetes // Eur. J. Endocrinol. — 2005. — Vol. 153. — P. 907—913.

Cheng S.W., Lu J.M., Pan C.U. et al. Studies of pharmacokinetic, pharmacodynamic properties and bioequivalence of recombinant insulin glargine injection in healthy man [in Chinese] // Chin. J. Diabetes. — 2010. — Vol. 18. — P. 387—393.

Cinek O., Pechová M., Kolousková S. et al. Autoantibodies to GAD65, IA2 and insulin in Czech children with type 1 diabetes // Cas. Lek. Cesk. — 2000. — Vol. 27, N 139 (19). — Р. 599—603.

Daneman D., Fishman L., Clarson C. Factors affecting insulin anti­body binding in children with insulin-dependent diabetes mellitus // Clin. Invest. Med. — Medecine Clinique et Experimentale. — 1987. — Vol. 10. — P. 480—483.

Davidson J.K. Transferring patients with insulin-dependent diabetes mellitus from animal-source insulins to recombinant DNA human insulin: clinical experience // Clinical Ther. — 1989. — Vol. 11. — P. 319—330.

Decochez K., Tits J., Coolens J.L. et al. High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry // Diabetes Care. — 2000. — Vol. 23, N 6. — Р. 838—844.

De Shazo R.D. Insulin allergy and insulin resistance: two immuno­logic reactions // Postgrad. Med. — 1978. — Vol. 63. — P. 85—92.

Devendra D., Franke B., Galloway T.S. et al. Distinct idiotypes of insulin autoantibody in autoimmune polyendocrine syndrome type 2 and childhood onset type 1 diabetes // J. Clin. Endocrinol. Metab. — 2004. — Vol. 89, N 10. — Р. 5266—5270.

Devendra D., Galloway T.S., Horton S.J., Wilkin T.J. Exploring the idiotypes of insulin antibodies as markers for remission in Type 1 diabetes // Diabet Med. — 2004. — Vol. 21, N 12. — Р. 1316—1324.

Dozio N., Scavini M., Beretta A., Sarugeri E., Sartori S., Belloni C., Dosio F., Savi A., Fazio F., Sodoyez J.C., Pozza G. Imaging of the buffering effect of insulin antibodies in the autoimmune hypoglycemic syndrome // J. Clin. Endocrinol. Metab. — 1998. — Vol. 83. — Р. 643–648.

EDQM: Insulin glargine [draft monograph] Pharmeuropa Online 2011;23:327–328. HYPERLINK «http://www.edqm.eu/store/images/ majbdd/201103071151570. Contents%20of%20Phpa2302E.pdf» www.edqm.eu/ store/images/majbdd/201103071151570. Contents% 20of%20Phpa2302E.pdf.[Aug;2012]. HYPERLINK «http://www.edqm.eu/store/images/ majbdd/201103071151570.Contents%20of%20 Phpa2302E.pdf» www.edqm.eu/store/images/ majbdd/ 201103071151570.Contents%20of%20 Phpa2302E.pdf.

Federlin K., Kelcorsky H., Maser E. Clinical aspects of immunity to insulin // Keck K., Erb P., eds. Basic and clinical aspects of immunity to insulin. — New York: Walter de Gruyter, 1981. — P. 250.

Fernandez Castaner M., Perez M., Maravall J. et al. Lack of rela­tionship between insulin antibodies, metabolic control and insulin requirements in type 1 diabetes [letter; comment] // Diabet. Med. — 1996. — Vol. 13. — P. 686—687.

Fineberg S.E., Kawabata T., FincoKent D. et al. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes: an analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial // J. Clin. Endocrinol. Metab. — 2005. — Vol. 90. — P. 3287—3294.

Fletcher J.A., Barnett A.H., Pyke D.A. et al. Transfer from animal insulins to semisynthetic human insulin: a study in four centres // Diabetes Res. — 1990. — Vol. 14. — P. 151—158.

Francis A.J., Hanning I., Alberti K.G. The influence of insulin antibody levels on the plasma profiles and action of subcutaneously injected human and bovine short acting insulins // Diabetologia. — 1985. — Vol. 28. — P. 330—334.

Francis A.J., Home P.D., Walford S., Alberti K.G., Mann N., Reeves W.G. Prevalence of morning hyperglycaemia: determinants of fasting blood glucose concentrations in insulin-treated diabetics.Diabet Med. — 1985. — Vol. 2. — Р. 89—94.

Füchtenbusch M., Karges W., Standl E. et al. Antibodies to bovine serum albumin (BSA) in type 1 diabetes and other autoimmune disorders // Exp. Clin. Endocrinol. Diabetes. — 1997. — Vol. 105, N 2. — Р. 86—91.

Ganz M.A., Unterman T., Roberts M., Uy R., Sahgal S., Samter M., Grammer L.C., Ganz M.A., Unterman T., Roberts M., Uy R., Sahgal S., Samter M., Grammer L.C. Resistance and allergy to recombinant human insulin // J. Allergy Clin. Immunol. — 1990. — Vol. 86. — P.45—51.

Gonen B., Goldman J., Baldwin D., Goldberg R.B., Ryan W.G., Blix P.M., Schanzlin D., Fritz K.J., Rubenstein A.H. Metabolic control in diabetic patients. Effect of insulin-secretory reserve (measured by plasma C-peptide levels) and circulating insulin antibodies. // Diabetes. — 1979. — Vol. 28. — Р. 749—753.

González de Pijem L., Nieves-Rivera F. Insulin autoantibodies: evidence of autoimmune disease among a group of Puerto Rican children with newly diagnosed type 1 diabetes mellitus // P. R. Health Sci. J. — 2001. — Vol.20, N 2. — Р. 161—164.

Goswami R., Jaleel A., Kochupillai N.P. Insulin antibody response to bovine insulin therapy: functional significance among insulin requiring young diabetics in India // Diabetes Res. Clin. Pract. — 2000. — Vol. 49. — Р. 7—15.

Grammer L. Insulin allergy // Clin. Rev. Allergy. — 1986. — Vol. 4. — Р. 189—200.

Grammer L.C., Chen P.Y., Patterson R. Evaluation and management of insulin allergy // J. Allergy. Clin. Immunol. — 1983. — Vol. 71. — Р. 250—254.

Grammer L.C., Roberts M., Buchanan T.A., Fitzsimons R., Met­­zger B.E., Patterson R. Specificity of immunoglobulin E and immunoglobulin G against human (recombinant DNA) insulin in human insulin allergy and resistance // J. Lab. Clin. Med. — 1987. — Vol. 109. — Р. 141—146.

Gray R.S., Borsey D.Q., Kurtz A., Rainbow S., Smith A.F., Elton R.A., Dun­­can L.J., Clarke B.F. Relationship of glycosylated haemoglobin to C-pep­­tide secretory status and antibody binding of insulin in insulin-depen­­dent diabetes // Horm. Metab. Res. — 1981. — Vol. 13. — Р. 599—603.

Gray R.S., Cowan P., Di Mario U., Elton R.A., Clarke B.F., Duncan L.J. Influence of insulin antibodies on pharmacokinetics and bio­­ava­ilability of recombinant human and highly purified beef insulins in in­­sulin dependent diabetics // Br. Med. J. Clin. Res. Ed. — 1985. — Vol. 290. — Р. 1687—1691.

Grunfeld C. Insulin resistance: pathophysiology, diagnosis, and therapeutic implications // Special Top Endocrinol. Metabol. — 1984. — Vol. 6. — Р. 193—240.

Hall T.R., Thomas J.W., Padoa C.J. [et al.] Longitudinal epitope analysis of insulin-binding antibodies in type 1 diabetes // Clin. Exp. Immunol. — 2006. — Vol.146, N 10. — Р. 9—14.

Hara K., Tobe K., Uchigata Y., Nakazono M., Yasuda K., Terauchi Y., Iwamoto Y., Akanuma Y., Kimura S., Kadowaki T. Antibody-mediated insulin resistance treated by cessation of insulin administration // Intern. Med. — 2000. — Vol. 39. — P. 143—145.

Héctor Garcia-Nares, María Isabel Leyva-Carmona, Neftalí Perez-Xochipa and Erwin Chiquete /Hypersensitivity reaction to a bio­similar insulin glargine // Journal of Diabetes. — 2015. — Vol. 7. — P. 155—157.

Hepner F., Czasar E., Roitinger E., Lubec G. Mass spectrometrical analysis of recombinant human growth hormone (Genotropin) reveals amino acid substitutions in 2 % of the expressed protein // Proteome Sci. — 2005. — N 3. — Р. 1—12.

Hirata Y., Ishizu H., Ouchi N. ET AL. Insulin autoimmunity in a case of spontaneous hypoglycemia // J. Japan Diab. Soc. — 1970. — Vol. 13. — P. 312—320.

Hirata Y., Uchigata Y. Insulin autoimmune syndrome in Japan // Diabetes Res. Clin. Pract. — 1994. — Vol. 24 (Suppl.). — S153—S157.

Holmberg H., Vaarala O., Sadauskaite-Kuehne V. et al. Higher prevalence of autoantibodies to insulin and GAD65 in Swedish compared to Lithuanian children with type 1 diabetes // Diabetes Res. Clin. Pract. — 2006. — Vol. 72, N 3. — Р. 308—314.

Home P. Biosimilar insulins // Diabetes Voice. — 2011. — N 56 (2). — Р. 41—43.

Hubinger A., Becker A., Gries F.A. Total insulin levels in type 1 diabetic patients with insulin antibodies and their effect on insulin requirement and metabolic control // Diabetes Res. — 1988. — Vol. 7. — P. 65—69.

Instituto Nacionalde Vigilanciade Medicamentosy Alimentos: Sala especializada de medicamentos y productos biológicos de la comisión revisora, Acta N 31. Ministerio de la Protección Social. — Bogata, Repúblicade Colombia, 2009. — http://web.invima.gov.co/portal/documents/portal/documents/root/acta312009_medicamentos.pdf. [Aug; 2012]. http://web.invima.gov.co/portal/documents/portal/documents/root/acta312009_medicamentos.pdf.

Jaeger C., Eckhard M., Brendel M.D., Bretzel R.G. Diagnostic algo­­rithm and management of immune-mediated complications asso­ciated with subcutaneous insulin therapy // Exp. Clin. Endocrinol. Diabetes. — 2004. — Vol. 112. — P. 416—421.

Jenkins N., Murphy L., Tyther R. Post-translational modifications of recombinant proteins: significance for biopharmaceuticals // Mol. Biotechnol. — 2008. — N 39. — Р. 113—118.

Kabadi U.M., Birkenholz M. Metabolic control following transfer from mixed bovine-porcine insulin to human insulin in subjects with IDDM: influence of the presence of insulin antibodies // Diabetes Res. — 1992. — Vol. 19. — P. 187—193.

Kahn C.R., Rosenthal A.S. Immunologic reactions to insulin: insulin allergy, insulin resistance, and the autoimmune insulin syndrome // Diabetes Care. — 1979. — Vol. 2. — P. 283—295.

Keilacker H., Rjasanowski I., Ziegler M. et al. Insulin antibodies in juvenile diabetes mellitus: correlations to diabetic stability, insulin requirement and duration of insulin treatment // Horm. Metab. Res. — 1982. — Vol. 14. — P. 227—232.

Kerp L., Kasemir H. High and low affinity insulin antibodies // Acta Endocrinol. — 1976. — Vol. 205 (Suppl.). — P. 211—222.

Kim M.R., Sheeler L.R., Mansharamani N. et al. Insulin antibodies and hypoglycemia in diabetic patients. Can a quantitative analysis of antibody binding predict the risk of hypoglycemia? // Endocrine. — 1997. — Vol. 6. — P. 285—291.

Kirsty D. Ratanji, Jeremy P. Derrick, Rebecca J. Dearman, Ian Kimber. Immunogenicity of therapeutic proteins: Influence of aggregation // J. Immunotoxicol. — 2014. — Vol. 11 (2). — P. 99—109.

Koyama R., Nakanishi K., Kato M. et al. Hypoglycemia and hyper­glycemia due to insulin antibodies against therapeutic human insulin: treatment with double filtration plasmapheresis and pred­nisolone // Am. J. Med. Sci. — 2005. — Vol. 329. — P. 259—264.

Kozlowski S., Swann P. Current and future issues in the manufacturing and development of monoclonal antibodies // Adv. Drug Del. Rev. — 2006. — N 58. — Р. 707—722.

Kresse G-B. Biosimilars — science, status, and strategic perspective // Eur. J. Pharm. Biopharm. — 2009. — N 72 (3). — Р. 479—486.

Kuhlmann M., Covic A. The protein science of biosimilars // Nephrol. Dial Transplant. — 2006. — N 21 (Suppl. 5). — v4—v8. doi:10.1093/ ndt/gfl 474.

Lahtela J.T., Knip M., Paul R. et al. Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro: a case report // Diabetes Care. — 1997. — Vol. 20. — P. 71—73.

Lam H.C., Ho L.T., Tang K.T. et al. Immunogenicity of highly purified porcine and human insulins in diabetic patients with high titers of insulin antibody. Taiwan I Hsueh Hui Tsa Chih // J. Formosan. Med. Assoc. — 1989. — Vol. 88. — P. 346—351.

Liu M., Zhou Z., Yan J. et al. A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with type 1 diabetes mellitus // BMC Endocr. Disord. — 2016. — Vol. 26, N 16 (1). — Р. 67.

Livneh A., Avraham H., Bistritzer T. et al. Deleterious effect of anti-insulin antibodies on diabetes control // Isr. J. Med. Sci. — 1990. — Vol. 26. — P. 11—15.

Ludvigsson J. Insulin antibodies in diabetic children treated with mono­­component porcine insulin from the onset: relationship to B-cell function and partial remission // Diabetologia. — 1984. — Vol. 26. — P. 138—141.

Makela A.L., Akerblom H.K., Makela P. Insulin antibodies in diabetic children treated with highly purified porcine NPH insulin. Compa­rison of results obtained by three methods of insulin antibody determination // Diabete Metab. — 1982. — Vol. 8. — P. 341—348.

Maneschi F., Fineberg S.E., Kohner E.M. Successful treatment of immune-mediated insulin resistance by human insulin (recombinant DNA) // Diabetes Care. — 1982. — Vol. 5 (Suppl. 2). — P. 175—179.

Misra A. Are biosimilars really generics? // Expert Opin. Biol. Ther. — 2010. — N 10 (4). — Р. 489—494.

Miyoshi H., Yanigasawa K., Obara S.K.T. Response to insulin lispro in a case of diabetes complicated by liver cirrhosis that could not be controlled with high-dose human insulin // J. Japan Diab. Soc. — 2003. — Vol. 46. — P. 145—149.

Mizuhashi S., Nakamura K., Mori Y. et al. Insulin allergy and immunologic insulin resistance caused by interleukin-6 in a patient with lung cancer // Care. — 2006. — Vol. 29. — P. 1711—1712.

Moises R.S., Sa J.R., Chacra A.R., Russo E.M. Relationship between insulin antibodies and metabolic control in type I diabetes mellitus // Braz. J. Med. Biol. Res. — 1990. — Vol. 23. — P. 1243—1252.

Murphy N.P., Keane S.M., Ong K.K. et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens // Diabetes Care. — 2003. — Vol. 26. — P. 799—804. — Doi: 10.2337/diacare.26.3.799.

Mustaffa B.E., Daggett P.R., Nabarro J.D. Insulin binding capacity in pa­­tients changed from conventional to highly purified insulins: an indicator of likely response // Diabetologia. — 1977. — Vol. 13. — P. 311—315.

Patterson R., Mellies C.J., Roberts M. Immunologic reactions against insulin. II. IgE anti-insulin, insulin allergy and combined IgE and IgG immunologic insulin resistance // J. Immunol. — 1973. — Vol. 110. — P. 1135—1145.

Patterson R., Roberts M., Grammer L.C. Insulin allergy: re-evaluation after two decades // Ann. Allergy. — 1990. — Vol. 64. — P. 459—462.

Peters A., Klose O., Hefty R. et al. The influence of insulin antibodies on the pharmacokinetics of NPH insulin in patients with type 1 diabetes treated with human insulin // Diabet Med. — 1995. — Vol. 12. — P. 925—930.

Pihoker C., Gilliam L.K., Hampe Ch.S., Lernmark Å. Autoantibodies in Diabetes // Diabetes. — 2005. — Vol. 54, N 1. — S52—S61.

Potter K.N., Wilkin T.J. The molecular specificity of insulin auto­antibodies // Diabetes Metab. Res. Rev. — 2000. — Vol. 16, N 5. — Р. 338—353.

Questions and answers on generic medicines. EMEA document. EMEA/393905/2006. — London, UK: European Medicines Agency. — 2007. Available from: www.emea.europa.eu/pdfs/human/ pcwp/ 39390506en.pdf [Last accessed 30 January 2010].

Raile K., Noelle V., Landgraf R., Schwarz H.P. Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes // Exp. Clin. Endocrinol. Diabetes. — 2001. — Vol. 109. — P. 393—396.

Resistance and allergy to recombinant human insulin // J. Allergy Clin. Immunol. — 1990. — Vol. 86. — P. 45—51.

Sabbah E., Savola K., Kulmala P. et al. Diabetes-associated auto­antibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. The Childhood Diabetes In Finland Study Group // J. Clin. Endocrinol. Metab. — 1999. — Vol. 84, N 5. — Р. 1534—1539.

Sakamoto N., Maruyama M., Tsuruoka A., Tajima N. A type 1 diabetic patient with prolonged fasting hypoglycemia and postpran­dial hyperglycemia due to insulin autoimmune syndrome-like insulin antibodies // J. Japan Diab. Soc. — 2002. — Vol. 45. — P. 471—476.

Sakata S., Matsuda M., Komaki T., Miura K. Effect of anti-insulin antibodies on glycemic control in insulin treated diabetic patients // Immunol. Invest. — 1986. — Vol. 15. — P. 791—799.

Salardi S., Cacciari E., Steri L. et al. An 8-year follow-up of anti-insulin antibodies in diabetic children: relation to insulin autoanti­bodies, HLA type, beta-cell function, clinical course and type of in­­sulin therapy // Acta Paediatr. — 1995. — Vol. 84, N 6. — Р. 639—645.

Schlosser M., Koczwara K., Kenk H. In insulin-autoantibody-positive children from the general population, antibody affinity identifies those at high and low risk // Diabetologia. — 2005. — Vol. 48, N 9. — Р. 1830—1832.

Schober E., Schoenle E., Van D.J., Wernicke-Panten K. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus // J. Pediatr. Endocrinol. Metab. — 2002. — Vol. 15. — P. 369—376. — Doi: 10.1515/JPEM.2002.15.4.369.

Siljander H., Härkönen T., Hermann R. et al. Role of insulin autoantibody affinity as a predictive marker for type 1 diabetes in young children with HLA-conferred disease susceptibility // Diabetes Metab. Res. Rev. — 2009. — Vol. 25, N 7. — Р. 615—622.

Takahashi S., Oida K., Miyamori I. A 75-year-old type 2 diabetes mellitus case responding strikingly troglitazone: possible mechanism of insulin resistance induced by insulin antibody // Nippon. Ronen. Igakkai. Zasshi. — 2000. — Vol. 37. — P. 344—348.

Takayama-Hasumi S., Eguchi Y., Sato A. et al. Insulin autoimmune syndrome is the third leading cause of spontaneous hypoglycemic attacks in Japan // Diabetes Res. Clin. Pract. — 1990. — Vol. 10. — P. 211—214.

The Commission of the European Communities (2003) Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use // In Official Journal of the European Union. — L159. — Р. 46—94. — http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:159:0046:0094:EN:PDF.

The European Parliament and the Council of the European Union (2001) Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use // In Official Journal of the European Union. — L311. — Р. 67—128. — http://eur-lex.europa.eu/LexUriServ/LexUriServ. do?uri=OJ:L:2001:311:0067:0128:EN:PDF.

Thomas J.W., Virta V.J., Nell L.J. Idiotypic determinants on human anti-insulin antibodies are cyclically expressed // J. Immunol. — 1986. — Vol. 137. — P. 1610—1615.

Tiittanen M., Knip M., Vaarala O. Anti-insulin activity in IgG-fractions from children with newly-diagnosed type 1 diabetes and negative for insulin autoantibodies // Autoimmunity. — 2004. — Vol. 37, N 1. — Р. 45—49.

Uchigata Y., Kuwata S., Tsushima T. et al. Patients with Graves disease who developed insulin autoimmune syndrome (Hirata disease) possess HLA-Bw62/Cw4/DR4 carrying DRB1*0406 // J. Clin. Endocrinol. Metab. — 1993. — Vol. 77. — P. 249—254.

Vaarala O., Knip M., Paronen J. et al. Cow’s milk formula feeding induces primary immunization to insulin in infants at genetic risk for type 1 diabetes // Diabetes. — 1999. — Vol. 48, N 7. — Р. 1389—1394.

Van Haeften T.W., Heiling V.J., Gerich J.E. Adverse effects of insulin antibodies on postprandial plasma glucose and insulin profiles in diabetic patients without immune insulin resistance: implications for intensive insulin regimens // Diabetes. — 1987. — Vol. 36. — P. 305—309.

Van Haeften T.W., Krom B.A., Gerich J.E. Prolonged fasting hypo­glycemia due to insulin antibodies in patient with non-insulin-dependent diabetes mellitus: effect of insulin withdrawal on insulin-antibody-binding kinetics // Diabetes Care. — 1987. — Vol. 10. — P. 160—163.

VanHaeften T.W., Bolli G.B., Dimitriadis G.D. et al. Effect of insulin antibodies and their kinetic characteristics on plasma free insulin dynamics in patients with diabetes mellitus // Metabolism. — 1986. — Vol. 35. — P. 649—656.

Verma M., Hazra P., Iyer H. et al. Basalog® is similar to Lantus® in producing glycemic control in patients with type 1 diabetes mellitus on multiple daily insulin regimens // Int. J. Diabetes Dev. Countries. — 2011. — Vol. 31. — P. 26—31.

Waldhausl W.K., BratuschMarrain P., Kruse V. Et al. Effect of insulin antibodies on insulin pharmacokinetics and glucose utilization in insulin-dependent diabetic patients // Diabetes. — 1985. — Vol. 34. — P. 166—173.

Walford S., Allison S.P., Reeves W.G. The effect of insulin antibodies on insulin dose and diabetic control // Diabetologia. — 1982. — Vol. 22. — P. 106—110.

Walsh G. Therapeutic insulins and their large-scale manufacture // Appl. Microbiol. Biotechnol. — 2005. — N 67. — Р. 151—159.

Williams A.J., Norcross A.J., Dix R.J. et al. The prevalence of insulin autoantibodies at the onset of Type 1 diabetes is higher in males than females during adolescence // Diabetologia. — 2003. — Vol. 46, N 10. — Р. 1354—1356.

Witters L.A., Ohman J.L., Weir G.C. et al. Insulin antibodies in the pathogenesis of insulin allergy and resistance // Am. J. Med. — 1977. — Vol. 63. — P. 703—709.

Wredling R., Lins P.E., Adamson U. Prevalence of anti-insulin anti­bodies and its relation to severe hypoglycaemia in insulin-treated diabetic patients // Scand J. Clin. Lab. Invest. — 1990. — Vol. 50. — P. 55—557.

Young Hwa Kong, Min Sun Kim, Dae-Yeol Lee. Comparison of the prevalence of islet autoantibodies according to age and disease duration in patients with type 1 diabetes mellitus // Ann. Pediatr. Endocrinol. Metab. — 2013. — Vol. 18 (2). — P. 65—70.

Zhu L., He L., Gu Q. et al. A study on the control of fasting and postprandial hyperglycemia by glargine insulin combined with oral hypoglycemic agent [in Chinese] // Chin. J. Diabetes. — 2009. — Vol. 17. — P. 690—692.


Посилання

  • Поки немає зовнішніх посилань.



Видавнича група «ВІТ-А-ПОЛ»